Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 5/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.46 |
| ▸ | NPC1 | O15118 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | RELA | Q04206 | 1/20 | 0.46 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | ALOX15B | O15296 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29620897 | 1.00 | L3MBTL1 (0.48) | L3MBTL1HSD17B10RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL5258529 | 0.83 | POLB (0.50) | L3MBTL1HSD17B10RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL6482247 | 0.80 | L3MBTL1 (0.49) | L3MBTL1HSD17B10RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL30902133 | 0.79 | CXCR2 (0.59) | L3MBTL1HSD17B10RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL18059460 | 0.79 | L3MBTL1 (0.48) | L3MBTL1HSD17B10RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL11973215 | 0.79 | L3MBTL1 (0.48) | L3MBTL1HSD17B10RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL30553438 | 0.79 | L3MBTL1 (0.48) | L3MBTL1HSD17B10RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL15359704 | 0.79 | L3MBTL1 (0.48) | L3MBTL1HSD17B10RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL16011599 | 0.79 | L3MBTL1 (0.50) | L3MBTL1HSD17B10RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL5648662 | 0.79 | L3MBTL1 (0.48) | L3MBTL1HSD17B10RAB9ASMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001870-A1 | INHIBITOR COMPOUNDS | Cincera Therapeutics Pty Ltd (AU) | 2026-01-01 | — | — | US | disclosed |
| US-12448371-B2 | Inhibitor compounds | Cincera Therapeutics Pty Ltd (AU) | 2025-10-21 | — | — | US | disclosed |
| US-20240010641-A1 | N-Linked Glycosylation Inhibitors and Methods of Using Same | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-01-11 | — | — | US | disclosed |
| US-20230212122-A1 | MITOCHONDRIAL TARGETING COMPOUNDS FOR THE TREATMENT OF ASSOCIATED DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-07-06 | — | — | US | disclosed |
| US-20230212122-A1 | MITOCHONDRIAL TARGETING COMPOUNDS FOR THE TREATMENT OF ASSOCIATED DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-07-06 | — | — | US | disclosed |
| US-20230212122-A1 | MITOCHONDRIAL TARGETING COMPOUNDS FOR THE TREATMENT OF ASSOCIATED DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-07-06 | — | — | US | disclosed |
| EP-4157263-A1 | MITOCHONDRIAL TARGETING COMPOUNDS FOR THE TREATMENT OF ASSOCIATED DISEASES | The Regents Of The University Of Michigan (US) | 2023-04-05 | — | — | EP | disclosed |
| EP-3684357-B1 | HETEROARYL ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | MERCK SHARP & DOHME LLC (US) | 2022-12-28 | — | — | EP | disclosed |
| US-20220274970-A1 | INHIBITOR COMPOUNDS | Cincera Therapeutics Pty Ltd (AU) | 2022-09-01 | — | — | US | disclosed |
| EP-4003986-A1 | INHIBITOR COMPOUNDS | Cincera Therapeutics Pty Ltd (AU) | 2022-06-01 | — | — | EP | disclosed |
| US-20080188502-A1 | New Compounds I | ASTRAZENECA AB (SE) | 2008-08-07 | — | — | US | disclosed |
| US-20080188502-A1 | New Compounds I | ASTRAZENECA AB (SE) | 2008-08-07 | — | — | US | disclosed |
| US-20080188502-A1 | New Compounds I | ASTRAZENECA AB (SE) | 2008-08-07 | — | — | US | disclosed |
| US-7381728-B2 | Piperazine derivatives useful for the treatment of gastrointestinal disorders | GLAXO GROUP LIMITED (GB) | 2008-06-03 | — | — | US | disclosed |
| WO-2008002244-A2 | IMIDAZOL-PYRIMIDINE DERIVATIVES FOR TREATMENT OF DISEASES RELATED TO GLYCOGEN SYNTHASE KINASE (GSK3) | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | WO | disclosed |
| WO-2008002244-A2 | IMIDAZOL-PYRIMIDINE DERIVATIVES FOR TREATMENT OF DISEASES RELATED TO GLYCOGEN SYNTHASE KINASE (GSK3) | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | WO | disclosed |
| US-20070259877-A1 | Piperazine Derivatives Useful for the Treatment of Gastrointestinal Disorders | GLAXO GROUP LIMITED | 2007-11-08 | — | — | US | disclosed |
| EP-1778679-A1 | PIPERAZINE DERIVATIVES USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | GLAXO GROUP LIMITED (GB) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006134481-A1 | INHIBITORS OF 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE 1 | PFIZER INC. (US) | 2006-12-21 | — | — | WO | disclosed |
| WO-2006010629-A1 | PIPERAZINE DERIVATIVES USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | GLAXO GROUP LIMITED (GB) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240010641-A1 | N-Linked Glycosylation Inhibitors and Methods of Using Same | ENGASE, UGGT1, GALNT1 | L3MBTL1 2237/4885HSD17B10 1587/4885RAB9A 2616/4885 |
| US-20220274970-A1 | INHIBITOR COMPOUNDS | SERPINB1, MMP1, SSB | L3MBTL1 1286/4885HSD17B10 1525/4885RAB9A 987/4885 |
| US-20080188502-A1 | New Compounds I | SLC10A1, REN, SLC5A1 | L3MBTL1 4867/4885HSD17B10 827/4885RAB9A 824/4885 |
| US-20260001870-A1 | INHIBITOR COMPOUNDS | CES1, NCEH1, NR1H2 | L3MBTL1 1210/4885HSD17B10 53/4885RAB9A 1645/4885 |
| US-12448371-B2 | Inhibitor compounds | SERPINB1, MMP1, SSB | L3MBTL1 1286/4885HSD17B10 1525/4885RAB9A 987/4885 |
| US-20070259877-A1 | Piperazine Derivatives Useful for the Treatment of Gastrointestinal Disorders | GHSR, GHRHR, GIPR | L3MBTL1 4881/4885HSD17B10 1963/4885RAB9A 1000/4885 |
| US-20230212122-A1 | MITOCHONDRIAL TARGETING COMPOUNDS FOR THE TREATMENT OF ASSOCIATED DISEASES | TFAM, CS, FH | L3MBTL1 3301/4885HSD17B10 464/4885RAB9A 839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.